WSGR logoWSGR logo
Ty Kayam
Of Counsel
Regulatory
Seattle

D206-883-2607

Download vCard
Open PDF

Ty Kayam is Of Counsel in the Seattle office of Wilson Sonsini Goodrich & Rosati, where she advises companies and investors on regulatory strategy for health technology products, with a particular focus on health AI, digital health, wearables, medical robotics, and health data infrastructure. She counsels clients throughout product development and commercialization and advises on health regulatory issues arising in financings, investments, partnerships, and strategic transactions. Her practice draws on experience at the FDA, Microsoft, and a national health information network, combining regulatory insight, technical fluency, and a systems-level understanding of how health technologies are developed, deployed, and scaled.

Prior to joining Wilson Sonsini, Ty served as the first attorney in the FDA's Digital Health Center of Excellence, where she worked on the agency's regulatory approach to emerging health technologies, including generative AI-enabled medical devices. Her work focused on performance validation, evidentiary expectations, pre- and post-market regulatory issues, and predetermined change control plans (PCCPs). She also worked on U.S. and international regulatory alignment and advised on cross-jurisdictional matters involving Canada, the United Kingdom, and the European Union.

Previously, Ty was senior corporate counsel for Microsoft's health AI product portfolio and supported the company's global health regulatory and policy strategy, including developing compliance frameworks for health products under emerging EU regulations. Before Microsoft, she was an attorney at a national health information network, where she worked on the infrastructure that enables health technologies to exchange data in practice. This included matters related to interoperability, information blocking, EHR connectivity, APIs, and clinical data exchange.

Ty is a frequent speaker and commentator on health technology law, AI regulation, and health data policy. She serves as a peer reviewer for BMJ Digital Health & AI and has taught health technology law as an adjunct professor at Seattle University School of Law. She has also guest lectured at law schools throughout the United States and Canada. She is fluent in Telugu and conversational in Hindi.

Experience

Ty Kayam is Of Counsel in the Seattle office of Wilson Sonsini Goodrich & Rosati, where she advises companies and investors on regulatory strategy for health technology products, with a particular focus on health AI, digital health, wearables, medical robotics, and health data infrastructure. She counsels clients throughout product development and commercialization and advises on health regulatory issues arising in financings, investments, partnerships, and strategic transactions. Her practice draws on experience at the FDA, Microsoft, and a national health information network, combining regulatory insight, technical fluency, and a systems-level understanding of how health technologies are developed, deployed, and scaled.

Prior to joining Wilson Sonsini, Ty served as the first attorney in the FDA's Digital Health Center of Excellence, where she worked on the agency's regulatory approach to emerging health technologies, including generative AI-enabled medical devices. Her work focused on performance validation, evidentiary expectations, pre- and post-market regulatory issues, and predetermined change control plans (PCCPs). She also worked on U.S. and international regulatory alignment and advised on cross-jurisdictional matters involving Canada, the United Kingdom, and the European Union.

Previously, Ty was senior corporate counsel for Microsoft's health AI product portfolio and supported the company's global health regulatory and policy strategy, including developing compliance frameworks for health products under emerging EU regulations. Before Microsoft, she was an attorney at a national health information network, where she worked on the infrastructure that enables health technologies to exchange data in practice. This included matters related to interoperability, information blocking, EHR connectivity, APIs, and clinical data exchange.

Ty is a frequent speaker and commentator on health technology law, AI regulation, and health data policy. She serves as a peer reviewer for BMJ Digital Health & AI and has taught health technology law as an adjunct professor at Seattle University School of Law. She has also guest lectured at law schools throughout the United States and Canada. She is fluent in Telugu and conversational in Hindi.

Focus Areas
Recent Insights
Alerts
FDA Announces Funding Opportunity for Research on Digital Health Technologies in Drug and Biologic Development
Key Takeaways
Learn More
Alerts
CMS Proposes Payment Frameworks for “Software as a Medical Service”
On July 2, 2026, the Centers for Medicare and Medicaid Services (CMS) released the calendar year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule and on July 14, 2026, subsequently released the CY 2027 Physician Fee Schedule (PFS) proposed rule.1 These proposed rules establish a newly named Medicare payment category, Software as a Medical Service (SaMS), for software that supports clinical decision-making through algorithmic analysis.2 This is CMS’ first effort to pay for software-based clinical services in a structural way as their own category rather than as a cost buried inside reimbursement for another procedure. The consequential impact is that CMS would create a new reimbursement vehicle for software and AI-enabled products to be reimbursed as standalone services in the future. The proposal is worth close attention from stakeholders because Medicare reimbursement often determines the success of software or AI products intended for clinical purposes. Comments are due August 31, 2026, on the OPPS rule and September 14, 2026, on the PFS rule.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.